Colonic (81%), gastric, pancreatic (78%) and lung carcinomas revealed a high proportion of strongly positive tumours, suggesting EpCAM is an attractive target for pan-carcinoma immunotherapy (Went et al, 2004). Here, EPCAM is linked to neoplasm.